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IMPORTANCE Although growing evidence points to highly indolent behavior of encapsulated
follicular variant of papillary thyroid carcinoma (EFVPTC), most patients with EFVPTC are
treated as having conventional thyroid cancer.
OBJECTIVE To evaluate clinical outcomes, refine diagnostic criteria, and develop a
nomenclature that appropriately reflects the biological and clinical characteristics of EFVPTC.
DESIGN, SETTING, AND PARTICIPANTS International, multidisciplinary, retrospective study of
patients with thyroid nodules diagnosed as EFVPTC, including 109 patients with noninvasive
EFVPTC observed for 10 to 26 years and 101 patients with invasive EFVPTC observed for 1 to
18 years. Review of digitized histologic slides collected at 13 sites in 5 countries by 24 thyroid
pathologists from 7 countries. A series of teleconferences and a face-to-face conference were
used to establish consensus diagnostic criteria and develop new nomenclature.
MAIN OUTCOMES ANDMEASURES Frequency of adverse outcomes, including death from
disease, distant or locoregional metastases, and structural or biochemical recurrence, in
patients with noninvasive and invasive EFVPTC diagnosed on the basis of a set of
reproducible histopathologic criteria.
RESULTS Consensus diagnostic criteria for EFVPTCwere developed by 24 thyroid
pathologists. All of the 109 patients with noninvasive EFVPTC (67 treated with only
lobectomy, none received radioactive iodine ablation) were alive with no evidence of disease
at final follow-up (median [range], 13 [10-26] years). An adverse event was seen in 12 of 101
(12%) of the cases of invasive EFVPTC, including 5 patients developing distant metastases,
2 of whom died of disease. Based on the outcome information for noninvasive EFVPTC, the
name “noninvasive follicular thyroid neoplasmwith papillary-like nuclear features” (NIFTP)
was adopted. A simplified diagnostic nuclear scoring schemewas developed and validated,
yielding a sensitivity of 98.6% (95% CI, 96.3%-99.4%), specificity of 90.1% (95% CI,
86.0%-93.1%), and overall classification accuracy of 94.3% (95% CI, 92.1%-96.0%) for
NIFTP.
CONCLUSIONS AND RELEVANCE Thyroid tumors currently diagnosed as noninvasive EFVPTC
have a very low risk of adverse outcome and should be termed NIFTP. This reclassification will
affect a large population of patients worldwide and result in a significant reduction in
psychological and clinical consequences associated with the diagnosis of cancer.
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T he increasing incidence of cancer worldwide is multi-factorial, attributable to population longevity, chang-ing environmental and lifestyle factors, and increased
surveillance. Thyroid cancer is a prime example forwhich in-
tensified surveillance has resulted in an increasing incidence
ofearly cancerswith indolentbehavior,1,2 aphenomenoncom-
monlydescribedascancer “overdiagnosis.”3The increasing in-
cidence is solely attributable to papillary thyroid carcinoma
(PTC), a tumor named for its papillary growth pattern, al-
though thedefiningdiagnostic criteria are actually thenuclear
features of neoplastic cells.4 Aside from the enhanced screen-
ing, another important factor contributing to this phenom-
enon is the increase in diagnosis of a variant of PTC known as
the follicular variant of PTC (FVPTC).5
The follicular variant of PTCwas broadly recognized in the
mid-1970sasatumorcomposedofneoplasticfolliclesratherthan
papillae,butwith follicular cells showingnuclear featureschar-
acteristicofPTC.4Twomainsubtypesareknowntooccur: infil-
trative (or nonencapsulated) and encapsulated.6(pp100-109)7
EncapsulatedFVPTC(EFVPTC)has increased in incidencebyan
estimated2- to3-foldover thepast2 to3decadesandmakesup
10%to20%ofall thyroidcancerscurrentlydiagnosed inEurope
andNorthAmerica (eTable 1 in the Supplement).5,8
EncapsulatedFVPTCisachallengingandcontroversialdiag-
nosis inthyroidglandpathology. Inthosetumorsthathavenoin-
vasion, the diagnosis of cancer rests exclusively on finding the
characteristicnuclei, assessmentofwhich inmanycases is sub-
jectiveandevencontentious, leadingtoconsistentlyhighinterob-
servervariability.9-11 Furthermore, studiesover thepastdecade
have demonstrated that FVPTC overall,12 and particularly
EFVPTC,hasanindolentbehaviorandisgeneticallydistinctfrom
infiltrativetumors.7,13-17Yet,mostpatientswithEFVPTCcontinue
tobetreatedsimilarlytothosewithconventionalPTC.Asidefrom
the stigmaof a “cancer” diagnosis and themorbidity of aggres-
sivetreatmentforPTC,patientsandhealthcareprofessionalshave
tocopewiththerapidly increasingcostsofcare forpatientswith
thyroidcancer,whichwereestimatedtoexceed$1.6billionin2013
in theUnited States alone.18
Recognizing the problem of overdiagnosis and overtreat-
ment of indolent cancers in many organs, the National Can-
cer Institute convened in 2012 a conference to evaluate this
problem. Following the conference, a statement from a num-
ber of participants emphasized the need to revise terminol-
ogy, replacing the word “cancer” when data emerge to sup-
port a more indolent designation.19 The goal of the current
project was to assemble an international group of expert pa-
thologists and clinicians to reexamine the entity currently
knownasEFVPTC through a reviewof a set of caseswith long
follow-up to (1) establish standardized diagnostic criteria and
(2) identify terminology thatwould appropriately address the
biological and clinical characteristics of this lesion.
Methods
Working Group
TheEndocrinePathologySocietyworkinggroupincluded24ex-
perienced thyroidpathologists (representing 7 countries and4
continents), 2endocrinologists, 1 surgeon,and1psychiatrist. In
addition,amolecularpathologist,abiostatistician,andathyroid
cancer survivor/patient advocate participated in the study.
Study Cohorts
For this retrospective study, a total of 268 tumors diagnosed as
EFVPTC using current histologic criteria were contributed by
workinggrouppathologists from13institutions(eMethodsinthe
Supplement)for inclusioninto2groups.Potentialcasesforgroup
1 includednoninvasiveEFVPTCwithnoradioiodine (RAI) treat-
mentandat least 10yearsof follow-up (n = 138).Potential cases
for group 2 includedEFVPTCwith vascular invasion and/or tu-
mor capsule invasion and at least 1 year of follow-up (n = 130).
Shorter follow-upforgroup2wasacceptedsoasnot tomissdis-
tantspreadorrecurrencewithinthefirstyears followingdiagno-
sis.Thecodedslidesweredigitizedintowhole-slideimagesusing
theAperioplatformandplacedona server accessible to theen-
tire group (http://image.upmc.edu:8080/NikiForov%20EFV
%20Study/view.apml). The study was performed under
institutional review board/ethics committee approval at 11
institutions, with exemption at 2 institutions, with a waiver of
informedconsentbecausethestudywasbasedonretrospective
analysis of existingmaterials.
Histologic Review and Discussions
Twenty-four working group pathologists independently re-
viewed the scanned slides andprovided their diagnoses in ac-
cordance with the existing criteria (eMethods in the Supple-
ment). The diagnoses were tabulated and the initial findings
were presented at the initiation of an 8-week series of weekly
teleconferences aimed at refining groups 1 and 2 and achiev-
ing consensus. At a face-to-face conference inBoston,Massa-
chusetts, onMarch 20 and 21, 2015, the findings of the study,
together with related molecular and clinical outcome infor-
mation, were discussed and the new nomenclature was
established by consensus (eMethods in the Supplement). A
nuclear scoring schemewas subsequentlydevelopedandvali-
dated as detailed in the eMethods in the Supplement.
Molecular Analysis
Molecular analysiswasperformedon37 cases initially submit-
tedfor inclusionintogroup1onwhichparaffinblockswereavail-
Key Points
Question Do clinical outcomes of noninvasive encapsulated
follicular variant of papillary thyroid carcinoma (EFVPTC) warrant
reclassification of this tumor as nonmalignant?
Findings This study evaluates cases of encapsulated follicular
variant of papillary thyroid carcinoma to establish consensus
diagnostic criteria and develop new nomenclature. Among 109
patients with noninvasive EFVPTC, most of whomwere treated
with lobectomy only and none with radioiodine, all were alive with
no evidence of disease at a median follow-up of 13 years.
Meaning Thyroid tumors currently diagnosed as noninvasive
EFVPTC have a very low risk of adverse outcome and should be
termed “noninvasive follicular thyroid neoplasms with
papillary-like nuclear features” (NIFTP).
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able, andon26newcasesofEFVPTCusedasavalidationset for
thenuclearscoreselectedfromthefilesof theDepartmentofPa-
thology, University of Pittsburgh. Total nucleic acidswere iso-
lated fromformalin-fixedandparaffin-embeddedtumor tissue
followingmanualmicrodissection.Molecularanalysiswasper-
formedusingThyroSeqv2panelaspreviouslydescribed.20The
assayuses targetednext-generationsequencinganalysis forde-
tecting point mutations and indels in 14 genes (AKT1, BRAF,
CTNNB1,GNAS,HRAS,KRAS,NRAS,PIK3CA,PTEN,RET,TP53,
TSHR,TERT,EIF1AX)and42genefusiontypesinvolvingtheRET,
BRAF,NTRK1,NTRK3,ALK,PPARG,andTHADAgenes.Samples
that showedmore than 5%ofmutant alleles (corresponding to
10%ofcellswithheterozygousmutation) forpointmutationsor
morethan100high-qualityreadscrossingthefusionpointof the
transcript were considered positive. The minimum depth of
coverage for each genewas 500×.
Statistical Analysis
Data analyseswere divided into a training phase and testing or
validationphase. In the trainingphase,23pathologists,blinded
tomoleculardiagnosis,provideda3-pointnuclear score (range,
0-3per case) for eachof 13 cases.With themoleculardata serv-
ing as the reference standard, a random-effects logistic regres-
sionmodel was fitted to predict molecular diagnosis based on
molecularstatusandindividualpathologist’snuclearscore.The
logistic model accounted for correlation among pathologists
evaluating the samecase.Thepredictedprobabilityof callinga
case positivewas computed and the cutoff providing themost
accuratedecisionwasascertained.Thismethoddetectedmini-
mal impactof individualpathologist, andthereforeasimplified
decisionrulethat ignoredtheindividualpathologistwasalsocal-
culated.This simplified rulewasselected forvalidation.Valida-
tion of the simplified rule was tested in a second cohort of 26
patients with molecular diagnoses. Once again, pathologists
(N = 22) blindly scored each case with a 3-point nuclear score.
Treating the22testpathologistsas independentandcombining
their evaluations, thedecision rule fromthe trainingphasewas
thensummarizedbycomputingsensitivity, specificity,positive
predictive value, and accuracy.
Results
Consensus Diagnostic Features of Encapsulated FVPTC
Reviewofrepresentativedigitalandstill imagesandsubsequent
discussions identified a list of major andminor diagnostic cri-
teriaforEFVPTCusedbythemajorityofthyroidpathologistspar-
ticipatinginthestudy(Box1,Figure1,andeFigure1intheSupple-
ment). Furthermore, as a result of the discussion, consensus
exclusioncriteria forEFVPTCwereaccepted (Box 1). The initial
review and rereview of cases in both groupswas conducted in
a blinded fashion, ie, without knowledge of follow-up.
Results of Initial andSubsequentReviewsofCases inGroup 1
The initial reviewof 138potential cases forgroup1 (noninvasive
EFVPTC) resulted in 105 (76%) cases having the diagnosis of
EFVPTC renderedby 12ormore (≥50%)pathologists andonly 1
casewithaconcordantdiagnosisofabenignnodulerenderedby
all 24 pathologists. Overall, the degree of expression of nuclear
featuresofPTCcorrelatedwiththeproportionofpathologistsren-
dering the diagnosis of EFVPTC (eFigure 2 in the Supplement).
Followingtheacceptanceof theaforementionedconsensus
diagnosticcriteria,30casesfromgroup1withthemostdisparate
diagnosesrenderedontheinitialreviewwererereviewedanddis-
cussed at teleconferences. As a result, 28 cases were excluded
fromgroup1becauseof insufficientdiagnosticnuclear features
ofPTC(n = 14),presenceof invasion (n = 6), at least 1%papillary
growthconsistentwithclassicalPTC(n = 4),orprominent(>30%)
solid/trabecular/insulargrowthpatternconsistentwitheithersolid
variant PTC or poorly differentiated thyroid carcinoma (n = 4).
Box 1. Consensus Diagnostic Criteria for the Encapsulated
Follicular Variant of Papillary Thyroid Carcinoma (EFVPTC)
Major Features
Encapsulation or clear demarcation
Follicular growth pattern
Nuclear features of papillary thyroid carcinoma (PTC)a:
Enlargement, crowding/overlapping
Elongation
Irregular contours
Grooves
Pseudoinclusionsb
Chromatin clearingc
Minor Features
Dark colloid
Irregularly shaped follicles
Intratumoral fibrosis
“Sprinkling” signd
Follicles cleft from stromad
Multinucleated giant cells within follicles
Features Not Seen/Exclusion Criteria
“True” papillaee >1%
Psammoma bodies
Infiltrative border
Tumor necrosis
Highmitotic activityf
Cell/morphologic characteristics of other variants of PTCg
a In a tumor with multifocal presence of PTC, most pathologists do not
require a specific minimal percentage of the tumor nodule to demonstrate
these features.
b Amajor and helpful diagnostic feature for all variants of PTC, although
uncommon in EFVPTC.
c Effacement of normal chromatin distribution with margination of chromatin
to membrane also known as “glassy nuclei” or “Orphan Annie” nuclei.
d As described and illustrated by Vanzati et al.21
e True papillae are defined as complex, arborizing papillae with fibrovascular
cores, lined by cells with nuclear features of PTC, and not associated with a
fine-needle aspiration area.
f At least 3 per 10 high-power fields (×40).
g Such as tall cell features, cribriform-morular variant, solid variant, etc.
Reclassification of a Variant of Thyroid Carcinoma Original Investigation Research
jamaoncology.com (Reprinted) JAMAOncology Published online April 14, 2016 E3
Downloaded From: http://oncology.jamanetwork.com/ by a Universita Torino User  on 06/20/2016
Copyright 2016 American Medical Association. All rights reserved.
Onecasewassubmittedandreviewedtwiceunderdifferentcoded
numbers; the duplicatewas eliminated. This resulted in a total
of 109 cases accepted as noninvasive EFVPTC in group 1.
Results ofMutational Analysis of Selected Cases in Group 1
Mutational analysiswasperformedon37cases initially submit-
tedasgroup1.Theanalysisassessedpointmutations in14genes
and42typesofgenefusions,whichare foundin approximately
90%ofPTC.22Clonalmolecular alterationsweredetected in25
(68%) of cases, with RAS mutations being the most common
(eTable2 in theSupplement).Noneof the5casesexcludedfrom
group1asaresultof insufficientnuclearfeatureshadidentifiable
mutations. In contrast, 21 (78%)of genetically characterized le-
sions remaining in group 1 revealed clonalmutations.
Results of Initial andSubsequentReviewsofCases inGroup2
Atotalof 130casesweresubmittedasgroup2,EFVPTCwith in-
vasion.These tumorshadthesamenuclear featuresandfollicu-
lar architecture as group 1 but, unlike group 1 cases, had vascu-
larand/ortumorcapsuleinvasion.Initialreviewyielded105(81%)
cases that were diagnosed as EFVPTCwith invasion by at least
50%of reviewers,whereas the remaining caseswere preferen-
tially called either classic PTC or infiltrative FVPTC (eTable 3 in
the Supplement). After review and discussion of 44 caseswith
themostdiscrepantdiagnosesatteleconferencesandapplication
oftheconsensusdiagnosticcriteria,29caseswereexcludedfrom
group2onthebasisofat least 1%papillarygrowth (n = 17), infil-
trativeborder (n = 8), lackof thenuclear featuresofPTC (n = 3),
or lackof invasion(n = 2).Asaresult, 101casesremainedingroup
2.This included80caseswith invasionof the tumorcapsule, 12
withvascular invasion, and9withboth invasion types (eFigure
3 in the Supplement).
Follow-up for Patients in Study Groups
Attheface-to-faceconference,thefollow-upinformationwaspro-
vided,assummarizedintheTable. Ingroup1,among109patients
observedfor10to26years,allwerealivewithnoevidenceofdis-
ease.Sixty-sevenof thesepatientswere treatedwith lobectomy
only, andnoneof themreceivedRAI. In group2, among 101pa-
tients,85patientswere treatedwithRAI, 15didnot receiveRAI,
andRAItreatmentstatusin1patientwasunknown.Patientswere
observedfor1to18years,and12(12%)registeredanadverseevent.
Of those, 5 patients developed distantmetastases (lung and/or
bone), 2 of whom died of disease. In addition, 1 patient had a
lymphnode recurrence, 1 hadpersistent disease, and 5hadde-
tectableserumthyroglobulinandwereconsideredtohaveeither
anindeterminateresponseorbiochemicallyincompleteresponse
to therapy (eTable4 in theSupplement).Among5patientswho
haddistantmetastases,atpresentation2tumorshadcapsular in-
vasion only, 1 had vascular invasion only, and 2 had both types
of invasion.
Revision of Tumor Nomenclature
Based on the outcome information available for tumors diag-
nosed using standardized criteria, new nomenclature was
developed. The goal was to offer a designation for the lesion
Figure 1. Gross and Histopathologic Features of the Tumor Currently Known as Encapsulated Follicular Variant
of Papillary Thyroid Carcinoma (EFVPTC)
Tumor with thin capsuleA Encapsulation and microfollicular growth pattern
of the tumor
B
Nuclear enlargement and elongationC Irregular nuclear contours and chromatin clearingD
10 cm
N
N
T
T
A, Gross appearance of a tumor with
thin capsule. B, Encapsulation
(arrowhead) andmicrofollicular
growth pattern of the tumor (T) as
compared with adjacent normal
thyroid (N) (hematoxylin-eosin
[H&E], original magnification ×100).
C, Major diagnostic nuclear features
including nuclear enlargement and
elongation, which is best appreciated
when nuclear size and shape of the
tumor (T) is compared with that of
adjacent normal tissue (N) (H&E,
original magnification ×400).
D, Irregular nuclear contours and
chromatin clearing (H&E, original
magnification ×400). Nuclear
pseudoinclusions and nuclear
grooves, as well as minor diagnostic
criteria, are illustrated in eFigure 1 in
the Supplement.
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currentlyknownasnoninvasiveEFVPTCthatwould reflect the
following characteristics:
1. mainmorphological features, ie, the follicular growth pat-
tern and nuclear features of PTC;
2. lack of invasion, which separates this tumor from invasive
EFVPTC;
3. clonalorigindeterminedbyfindingadrivermutation,which
indicates that the lesion is biologically a neoplasm; and
4. a very low risk of adverse outcomewhen the tumor is non-
invasive.
Additional considerationwas tousewords translatable to
other languages without losing their exact meaning. As a re-
sult, the term “noninvasive follicular thyroid neoplasm with
papillary-like nuclear features” (NIFTP) was accepted.
Diagnostic Nuclear Score
Toprovidesimplifiedandreproduciblecriteriaforthenuclearfea-
turesthatcouldassist inthediagnosisofNIFTPinroutinepathol-
ogypractice, the6mainconsensusnuclear features (Box1)were
groupedinto3categories:(1)sizeandshape(nuclearenlargement/
overlapping/crowding,elongation), (2)nuclearmembraneirregu-
larities (irregular contours, grooves, pseudoinclusions), and (3)
chromatincharacteristics (clearingwithmargination/glassynu-
clei).A3-pointscoringschemewasdeveloped,inwhicheachclass
ofnuclear featureswasassignedascoreof0or1,yieldingarange
of scores from0to3.Usingavisualguide for scoring thenuclear
features(eFigure4intheSupplement),30casesfromgroup1were
evaluatedby23pathologistswhowereblinded to the results of
molecularanalysisavailableon18oftheselesions(eTable5inthe
Supplement).Usingamolecularendpointas thereferencestan-
dardseparatingNIFTPfrombenignhyperplasticnodules,thescor-
ingschemedeliveredthemostaccurateclassificationwhenascore
of 0 or 1 was diagnostic of a benign nodule and a score of 2 or 3
wasdiagnosticofNIFTP.Thisapproachdemonstratedasensitiv-
ityof86.5%(95%CI,82.7%-90.3%),specificityof80.8%(95%CI,
73.8%-87.9%),andoverallaccuracyof85.0%(82.8%-90.3%).The
3-pointscoringschemewasthenvalidatedinanindependentset
of26newcaseswithmolecularendpoints(eTable6intheSupple-
ment). Using a0 to 1 vs 2 to 3 score separation, the 3-point scor-
ingschemeshowedasensitivityof98.6%(95%CI,96.3%-99.4%),
specificityof90.1%(95%CI,86.0%-93.1%), andoverall classifi-
cation accuracy of 94.3% (95%CI, 92.1%-96.0%).
Finaldiagnostic criteria forNIFTParesummarized inBox2.
Discussion
This studywasundertakento reexamine theclinical andpatho-
logicapproachtononinvasiveEFVPTC—athyroidtumorthat,de-
spite increasingevidenceof its indolentbehavior, isnonetheless
classifiedascancer.Theoutcomedataobtainedinthisstudysup-
port renaming this tumor in amanner thatmore accurately re-
flects its behavior. Indeed, inourhighly curatedcohort ofmore
than100noninvasiveEFVPTCstherewerenorecurrencesorother
manifestations of thedisease at amedian follow-upof 13 years.
This finding correlates with previous reports on noninvasive
EFVPTC. In theEnglish language literature,only2 (0.6%)of352
well-documentednoninvasiveencapsulated/well-circumscribed
FVPTCs recurred.14,15,23-27Oneof the recurred tumorshadbeen
incompletelyexcised,whereas intheothercasethenoninvasive
natureof the tumor remainsquestionable.Even if these2cases
ofrecurrenceareaccepted,thecombineddatasuggestthat inthe
absenceof invasion this lesionentails avery lowriskof adverse
outcome and therefore should not be termed cancer.
The new proposed terminology, NIFTP, reflects key histo-
pathologic features of this lesion, ie, lack of invasion, follicular
growthpattern,andnuclear featuresofPTC.Molecularanalysis
performedinthisstudyonalimitednumberofsamplesconfirmed
previousobservations16,28demonstrating thatmostof these le-
sionsaredrivenbyclonalgeneticalterationsandarethereforeneo-
plasmsratherthanhyperplasticproliferations.Whendefinedwith
strict histopathologic criteria, these tumors arenot expected to
showmolecular alterationsassociatedwithclassicPTC, suchas
BRAFV600Emutations. Instead,theydemonstrateahighpreva-
lence ofRAS and othermutations,which have been associated
with follicular-pattern thyroid tumors, including follicular
adenoma (FA), follicular thyroid carcinoma (FTC), and
Table. SummaryofFollow-up Information forPatients in theStudyGroups
Characteristic
Group 1
(Noninvasive EFVPTC)
(n = 109)
Group 2
(Invasive EFVPTC)
(n = 101)
Age, mean (range), y 45.9 (21-81) 42.8 (8-78)
Sex, No. (%)
Female 91 (83) 71 (70)
Male 18 (17) 30 (30)
Tumor size, mean (range),
cm
3.1 (1.1-9.0) 2.5 (0.6-5.5)
Extent of surgery
Lobectomy 67 15
Total thyroidectomy 42 86
Follow-up, y
Mean (range) 14.4 (10-26) 5.6 (1-18)
Median 13.0 3.5
Adverse events during
follow-up, No. (%)
0 12 (12)
Box 2. Diagnostic Criteria for NIFTP
1. Encapsulation or clear demarcationa
2. Follicular growth patternb with
<1% Papillae
No psammoma bodies
<30% Solid/trabecular/insular growth pattern
3. Nuclear score 2-3
4. No vascular or capsular invasionc
5. No tumor necrosis
6. No highmitotic activityd
a Thick, thin, or partial capsule or well circumscribed with a clear demarcation
from adjacent thyroid tissue.
b Includingmicrofollicular, normofollicular, or macrofollicular architecture
with abundant colloid.
c Requires adequate microscopic examination of the tumor capsule interface.
d Highmitotic activity defined as at least 3 mitoses per 10 high-power fields
(400×).
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EFVPTC.16,22,29Furthermore, tumorsanalyzedinthisstudyalso
recapitulate theFAtoFTCsequenceofprogressionwith theca-
pacity for invasion, suggesting thatNIFTP likely represents the
“benign” counterpart or precursor of the invasive EFVPTC
(Figure 2).
We have defined a set of reproducible diagnostic criteria
that accurately identifyNIFTP.Wehave also shown that given
themetastatic potential of the invasive tumors in group2, ad-
equate sampling of the tumor capsule interface to exclude in-
vasion is imperative before designating a nodule asNIFTP. To
our knowledge, adequacy of tumor capsule sampling has not
beendiscussed in the literature todatewith respect toFVPTC.
Precedent can be drawn from the approach to the encapsu-
latedFA/FTCtumors, inwhichhistologic assessmentof theen-
tire lesional capsule is preferable to exclude a minimally in-
vasive FTC.30 Thus, like FA, NIFTP should undergo extensive
review of the tumor capsule interface to exclude invasion.
The results of this study, togetherwithpreviously reported
observations, suggest thatwhenthediagnosisofNIFTP ismade
onthebasisofcarefulhistopathologicalexamination, thetumor
willhavea lowrecurrencerate, likely less than1%withinthefirst
15years.Ofnote,mostdifferentiatedthyroidcarcinomasrelapse
withinthefirstdecadeafter initial therapy,31althoughlaterecur-
rencesanddistantspreadaredocumented.32 Importantly,a large
proportion of patients with tumors diagnosed as NIFTP in the
presentstudyunderwent lobectomyonlyandnonereceivedRAI
ablation.Thissuggeststhatclinicalmanagementofpatientswith
NIFTP can be deescalated because they are unlikely to benefit
from immediate completion thyroidectomy and RAI therapy.
Stagingwouldbeunnecessary. Inadditiontoeliminatingthepsy-
chological impact of the diagnosis of cancer, thiswould reduce
complicationsof total thyroidectomy, riskof secondary tumors
following RAI therapy, and the overall cost of health care.33,34
AvoidanceofRAItreatmentalonewouldsavebetween$5000and
$8500perpatient (basedonUScost).35Decreasedlong-termsur-
veillancewouldaccountforanothersubstantialproportionofcost
reduction.
Conclusions
The results of this international and multidisciplinary study
establish that thyroid lesions currently diagnosed as nonin-
vasiveEFVPTCrepresentadistinct classof thyroid tumorswith
very low risk of adverse outcome. These tumors can be diag-
nosedusingasetof reproduciblediagnostic criteria andshould
be termed“noninvasive follicular thyroidneoplasmswithpap-
illary-like nuclear features” (NIFTP).We estimate that this re-
classification would affect more than 45000 patients world-
wide each year (eTable 7 in the Supplement), thereby
significantly reducing thepsychological burden,medical over-
treatment and expense, and other clinical consequences as-
sociated with a cancer diagnosis.
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